title: Medical versus surgical abortion methods for pregnancy in China: a cost-minimization analysis.
abstract: BACKGROUND
  Both medical and surgical abortions are popular in developing countries. However, the monetary costs of these two methods have not been compared.
  
  
  METHODS
  430 women seeking abortions were recruited in 2008. Either a medical or surgical method was used for the abortion. We adopted the perspective of a third-party payer. Cost-minimization analysis was used based on all charges for the overall procedures in an out-patient clinic in Guangzhou, China.
  
  
  RESULTS
  219 subjects (51%) chose a medical method (mifepristone and misoprostol), whereas 211 subjects (49%) chose a surgical method. The efficacy in the surgical group was significantly higher than in the medical group (100 vs. 90%, p < 0.001). Surgical abortion incurred much more costs than medical abortion on average after initial treatment. When the subsequent costs were accumulated within the 2-week follow-up, the mean total cost in the medical group increased significantly due to failure of abortion and persistent bleeding. Patients undergoing medical abortion eventually incurred equivalent expenses compared to patients undergoing surgical abortion (p = 0.42).
  
  
  CONCLUSIONS
  There was no difference in the mean final costs between the two abortion methods. Complications of persistent bleeding and failure to abort (requiring surgical intervention) in the medical treatment group increased the final mean total cost substantially.
authors: Department of Obstetrics and Gynecology, First Municipal Hospital of Guangzhou, Affiliated to Guangzhou Medical College, Guangzhou, China.
authors: Wei
authors: W
authors: Xia
authors: Shouzhang
authors: S
authors: She
authors: Tai Hing
authors: TH
authors: Lam
mesh_terms: D000019:Abortifacient Agents / Q000009:adverse effects / Q000191:economics*; D000028:Abortion, Induced / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D000293:Adolescent; D000328:Adult; D002681:China; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015735:Mifepristone / Q000009:adverse effects / Q000191:economics*; D016595:Misoprostol / Q000009:adverse effects / Q000191:economics*; D011247:Pregnancy; D016896:Treatment Outcome; D014619:Vacuum Curettage / Q000009:adverse effects / Q000191:economics*; D055815:Young Adult
chemical_list: D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone